(Total Views: 611)
Posted On: 12/04/2021 2:40:58 PM
Post# of 145871
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Yesterday I started tracing down the effects of cAMP on cancer. I ran across something much more interesting. I knew that CCR5 blockade would downregulate PD-L1 but I didn't know by how much. I had surmised that if it did so very effectively PD-1 inhibitors would be unnecessary. Looking at this study with maraviroc the answer is it downregulates PD-L1 massively. Take into account that maraviroc is most likely less effective at the task then leronlimab. If that combo trial at MD Anderson involves a PD-1 inhibitor than they might as well toss out that inhibitor.
https://jitc.bmj.com/content/8/1/e000228/url]
![1595222759_892.jpg](https://investorshangout.com/images/MYImages/1595222759_892.jpg)
https://jitc.bmj.com/content/8/1/e000228/url]
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)